Working Paper Review Version 1 This version is not peer-reviewed

The Rationale for Potential Pharmacotherapy of COVID-19

Version 1 : Received: 9 May 2020 / Approved: 10 May 2020 / Online: 10 May 2020 (18:26:04 CEST)

A peer-reviewed article of this Preprint also exists.

Saber-Ayad, M.; Saleh, M.A.; Abu-Gharbieh, E. The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals 2020, 13, 96. Saber-Ayad, M.; Saleh, M.A.; Abu-Gharbieh, E. The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals 2020, 13, 96.

Journal reference: Pharmaceuticals 2020, 13
DOI: 10.3390/ph13050096

Abstract

On 11 March 2020, the coronavirus disease (COVID-19) was defined by the World Health Organization as a pandemic. Severe acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus infection, causing (COVID-19), first appeared in Wuhan, China in December 2019 and spread rapidly all over the world. COVID-19 is being increasingly investigated in virology, epidemiology, and clinical management strategies. There is currently no established consensus on the standard of care in the pharmacological treatment of COVID-19 patients. However, certain medications suggested for other diseases tend to be potentially effective for treating this infection, although, so far, without clear evidence. Therapies include new agents which are currently tested in several clinical trials, in addition to other medications that have been repurposed as antiviral and immune-modulating therapies. Previous high-morbidity human coronavirus epidemics such as the 2003 SARS-CoV and the 2012 Middle East respiratory syndrome coronavirus (MERS-CoV) prompted the identification of compounds that could theoretically be active against the emerging coronavirus SARS-CoV-2. Moreover, the advances in molecular biology techniques and computational analysis allowed better recognition of the virus structure and quicker screening of chemical libraries to suggest potential therapies. This review aims to summarize rationalized pharmacotherapy considerations in COVID-19 patients, to serve as a tool for health care professionals at the forefront of clinical care during this pandemic. All the therapies reviewed require either additional drug development or randomized large-scale clinical trials to be justified for clinical use.

Subject Areas

COVID-19; redmdesivir; cholorquine; therapy; SARS-CoV-2

Comments (1)

Comment 1
Received: 14 May 2020
Commenter: Maha Saber-Ayad
The commenter has declared there is no conflict of interests.
Comment: ''The review has been published in Pharmaceuticals (open access). You can find the full text of the early version through this link. The updated version will include hyperlinks to all clinical trials mentioned in the article.
https://www.mdpi.com/1424-8247/13/5/96
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.